Kevin Dunleavy

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure that could be roug

Two months after UCB revealed the success of Bimzelx in a head-to-head trial aga

Gilead Sciences has broadened its partnership with Korean manufacturer Yuhan, agreeing to a 210 billion Korean won ($140 million) supply deal for active pharmaceutical ingredients (API) for an undi

Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth, which was an uptick from a year ago.

With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for its top-selling

Less than a month after an FDA advisory committee voted 6-3

After striking radiopharmaceutical supply deals with pharma giants Novartis and AstraZeneca within the last six months, Niowave is taking steps to meet growing demand for the alpha-emitting is

Korea's SK bioscience has signed a technology transfer and manufacturing deal with the Colombian government which will allow the South American nation to produce the company's chickenpox vaccine SKYVaricella.

In yet another round of Big Pharma layoffs in New Jersey, Johnson & Johnson is dismissing 56 employees at its corporate headquarters in New Brunswick,

AstraZeneca has fired another volley in its bladder cancer competition with Merck's Keytruda, with the FDA on Thursday